Onconova Therapeutics (NASDAQ: ONTX) Lowered to Hold at Zacks Investment Research

Onconova (NASDAQ: ONTX) was reduced by  Zacks Research  from a “acquire” ranking to a “hold” score in a research note issued to capitalists on Thursday, Zacks.com reports.

According to Zacks, “Onconova Therapeutics, Inc. runs as a clinical-stage biopharmaceutical company. It concentrates on finding as well as creating small particle drug prospects to deal with cancer. The Company‘s products under various stages of advancement include Rigosertib intravenous (IV), Rigosertib Oral, Rigosertib IV, ON 013105 and Recilisib. Onconova Therapeutics, Inc. is headquartered in Newtown, Pennsylvania. “

Several other equities research experts also lately discussed the firm. Noble Financial reissued a “get” score and also provided a $11.00 rate objective on shares of Onconova Therapeutics in a report on Thursday, September 23rd. Guggenheim dropped their cost target on Onconova Therapeutics from $29.00 to $12.00 and set a “buy” ranking on the stock in a research note on Tuesday, September 28th.

NASDAQ: ONTX opened at $2.25 on Thursday. Onconova Therapeutics has a twelve month low of $2.22 and also a twelve month high of $28.95. The business has a 50 day moving ordinary price of $2.90 and a two-hundred day moving average price of $4.16. The company has a market cap of $46.76 million, a P/E proportion of -1.82 and a beta of 1.67.

Onconova Therapeutics (NASDAQ: ONTX) last launched its quarterly revenues outcomes on Thursday, November 11th. The biopharmaceutical business reported ($ 0.22) incomes per share for the quarter, topping experts’ consensus quotes of ($ 0.33) by $0.11. Onconova Therapeutics had a negative return on equity of 59.78% and also a negative internet margin of 8,294.27%. The firm had income of $0.06 million throughout the quarter, compared to the consensus price quote of $0.06 million. Throughout the exact same quarter in the prior year, the company uploaded ($ 0.45) EPS. As a group, research experts anticipate that Onconova Therapeutics will certainly upload -1.18 EPS for the current year.

A variety of hedge funds have recently bought and sold shares of ONTX. GSA Capital Allies LLP got a brand-new position in Onconova Therapeutics throughout the third quarter worth $922,000. Hudson Bay Resources Management LP got a new placement in shares of Onconova Therapeutics in the 3rd quarter worth $635,000. Pura Vida Investments LLC purchased a brand-new setting in shares of Onconova Therapeutics in the 3rd quarter worth $575,000. CVI Holdings LLC acquired a new placement in shares of Onconova Therapeutics in the 3rd quarter worth $493,000. Finally, Dimensional Fund Advisors LP purchased a new placement in shares of Onconova Therapeutics in the second quarter worth $509,000. Hedge funds as well as various other institutional financiers own 13.36% of the business’s stock.

About Onconova Therapeutics

Onconova Therapeutics, Inc is a clinical-stage biopharmaceutical firm, which takes part in the recognition as well as advancement of oncology therapeutics. It focuses on finding and creating tiny particle medicine prospects to deal with cancer cells. The business was founded by Ramesh Kumar as well as E. Premkumar Reddy on December 22, 1998 and is headquartered in Newtown, PA

. Get a totally free duplicate of the Zacks research record on Onconova Therapeutics (ONTX).

For more details regarding research offerings from Zacks Investment Research, browse through Zacks.com.

This instant news alert was generated by narrative science technology and financial data from Market in order to give viewers with the fastest and also most exact coverage. This story was examined by Market’s editorial group prior to publication. 



Before you think about Onconova Therapeutics, you’ll wish to hear this.

Market tracks Wall Street’s top-rated and best doing research experts and also the stocks they suggest to their customers every day. Market has actually identified the 5 stocks that top analysts are quietly whispering to their clients to purchase currently prior to the wider market catches on … as well as Onconova Therapeutics had not been on the listing.

While Onconova Therapeutics presently has a “Buy” rating amongst analysts, top-rated experts believe these five stocks are much better acquires.